PREcision MApping and NEuromodulation After Spontaneous Intracerebral Hemorrhage: The PREMANE Trial
Key facts
- Who runs it
- National University Hospital, Singapore
- Where
- Singapore2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Transcranial Magnetic Stimulation
- Record updated
- 2 November 2026
Who can take part
- Age
- 21 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Aged 21 to 65 years old
- A radiologically confirmed diagnosis of SICH on baseline CT-imaging
- Able to communicate in English (including patients with dysphasia and those who are unable to write)
Who cannot take part
- Prior cognitive impairments
- Patients with hemorrhage related to trauma, tumor, ischemic stroke, vascular malformations, and other structural causes
- Patients with history of seizures or an epileptic
- Patients who have been diagnosed with or have a history of mental health conditions (any psychological disorders)
- Pregnant women
- Foreigners
- FMA-UE score > 46
- MoCA score > 25
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 65 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Spontaneous intracerebral haemorrhage (ICH) is a devastating form of stroke accounting for approximately 10-15% of all strokes globally. There is increasing evidence of younger working-age adults suffering from small-to-moderate sized spontaneous ICH, who develop significant motor and cognitive impairment after the event. These impairments contribute substantially to post-stroke functional morbidity and poor recovery, increasing care needs and decreasing economic productivity.
Read full original descriptionShow less
Existing neuromodulation trials in stroke rehabilitation have applied transcranial magnetic stimulation (TMS) at fixed anatomical targets using group-level brain maps, which overlooks the substantial inter-individual variability in the spatial topography of functional brain networks after ICH. Precision functional mapping techniques have demonstrated that individual-specific brain networks can be estimated using densely sampled resting-state functional MRI (rs-fMRI) data and multi-session hierarchical Bayesian models (MS-HBM). These individual-specific networks can identify personalised neuromodulation targets for navigated TMS (nTMS) to improve rehabilitation outcomes.
Intermittent Theta Burst Stimulation (iTBS) to the primary motor cortex (M1) has been shown to alter functional connectivity in a dose-dependent manner, while iTBS to the dorsolateral prefrontal cortex (DLPFC) improves attention and memory after left-hemispheric stroke. Precision neuromodulation using nTMS targeting individual-specific functional M1 and DLPFC areas for personalised stroke rehabilitation has yet to be sufficiently tested in high-quality clinical trials.
The PREMANE trial aims to use precision functional mapping in individual patients with spontaneous intracerebral hemorrhage to investigate inter-individual connectivity changes over time and after navigated neuromodulation to deliver personalised neurorehabilitation for patients with ICH.
The 2 groups in the trial
- Sham nTMS FirstSham treatment, for comparison
Participants will be randomized into two groups to determine the sequence of intervention (active neuromodulation or sham stimulation first). Randomization will be performed using a computer-generated allocation sequence by an independent party not involved in outcome assessment. Sham stimulation will be provided by a sham coil. Active neuromodulation will be provided by an active coil. The active neuromodulation protocol utilizes intermittent theta burst stimulation (iTBS). The stimulation parameters include: * Intensity of 90% of resting motor threshold (RMT) * 3 sessions per day over 5 consecutive days * 1800 pulses per session
Treatment: Transcranial Magnetic Stimulation
- Active nTMS FirstTreatment being tested
Participants will be randomized into two groups to determine the sequence of intervention (active neuromodulation or sham stimulation first). Sham stimulation will be provided by a sham coil. Active neuromodulation will be provided by an active coil. The active neuromodulation protocol utilizes intermittent theta burst stimulation (iTBS). The stimulation parameters include: * Intensity of 90% of resting motor threshold (RMT) * 3 sessions per day over 5 consecutive days * 1800 pulses per session
Treatment: Transcranial Magnetic Stimulation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07908264, who can take part
- Record updated
- 2 November 2026